Oral administration of fucoxanthin formulations elicited hierarchical improvements in obesity-related parameters in a formulation-dependent manner, with D-SLN > L-SLN > FN in reducing serum triglycerides, fasting glucose, and hepatic transaminases (ALT, AST) (Figure 4). This evidence concerns the gene GPT and obesity disorder.